Click here to close Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly. We suggest using a current version of Chrome, FireFox, or Safari.
XB-IMG-87036

Xenbase Image ID: 87036


Fig. 3. Example of a nonobvious disease model revealed by phenologs: a yeast model of angiogenesis. (A) The sets of 8 genes (considering only mouse/yeast orthologs) associated with mouse angiogenesis defects and 67 genes associated with yeast hypersensitivity to the hypercholesterolemia drug lovastatin significantly overlap, suggesting that the yeast gene set may predict angiogenesis genes. This prediction was verified in Xenopus embryos for eight genes (three from literature support and five based upon vascular expression patterns) (Fig. S3) and studied in detail for the case of the transcription factor sox13. (B) sox13 is expressed in developing Xenopus vasculature, as measured by in situ hybridization (also Fig. S4). (C) Morpholino (MO) knockdown of sox13 induces defects in vasculature, measured using in situ hybridization versus the vasculature markers erg (defects observed in 31 of 49 animals tested) or agtrl1 (12 of 19 animals tested) (Fig S5). Such defects are rare in untreated control animals and five base pair mismatch morpholino (MM) knockdowns (0 of 22 control animals tested with agtrl1, 2 of 46 tested with erg; 5 of 28 MM animals tested with erg). (D) Hemorrhaging (white arrows) is apparent in stage 45 Xenopus embryos because of dysfunctional vasculature following sox13 morpholino knockdown (12 of 50 animals tested; two also showed unusually small hearts with defective morphology; Right: magnification of yellow boxed region in Middle), but is rare in control animals (1 of 45 tested untreated animals, 1 of 22 sox13-MM knockdown animals tested). All phenotypes in Figs. 3 and 4 are significantly different from controls by χ2 tests (P < 0.001). (E) In an in vitro human umbilical vein endothelial cell model of angiogenesis, knockdown of human SOX13 by siRNA disrupts tube formation (an in vitro model for capillary formation) to an extent comparable to knockdown of a known effector of angiogenesis (HOXA9) and significantly more than untreated cells or cells transfected with an off-target (scrambled) negative control siRNA. (Scale bar, 100 μm.)

Image published in: McGary KL et al. (2010)

Copyright © 2010. Image reproduced with permission of the publisher and the copyright holder. This is an Open Access article distributed under the terms of the Creative Commons Attribution License.

GeneSynonymsSpeciesStage(s)Tissue
sox13.Ssox12, Sry, xSox12, xsox13X. laevisThroughout NF stage 32 to NF stage 35 and 36pharyngeal arch
otic vesicle
posterior cardinal vein
intersomitic vessel
intersomitic vein
central nervous system
brain
spinal cord
eye
duct of Cuvier

Image source: Published

Experiment + Assay Source Phenotypes and Disease
Xla Wt + sox13 MO + NF33/34-35/36 (in situ hybridization) Fig.3.C
Expression Phenotype
decreased amount erg.L expression in blood vessel
decreased amount erg.L expression in intersomitic vein
decreased amount erg.L expression in posterior cardinal vein
Xla Wt + sox13 MO + NF45 (whole-mount microscopy) Fig.3.D
Anatomical Phenotype
abnormal blood vessel morphology

Larger Image
Printer Friendly View

Return to previous page